Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules

Thyroid

Volumn 25, Issue 7, 2015, Pages 789-796

  Brauner, Eran ^a   Holmes, Brittany J ^a   Krane, Jeffrey F ^b   Nishino, Michiya ^c   Zurakowski, David ^d   Hennessey, James V ^c   Faquin, William C ^a   Parangi, Sareh ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFIRMA GENE EXPRESSION CLASSIFIER; ARTICLE; CLASSIFIER; COHORT ANALYSIS; CONTROLLED STUDY; CYTOLOGY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; GENE EXPRESSION; HUMAN; HURTHLE CELL THYROID NODULE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUBTOTAL THYROIDECTOMY; SURGICAL TECHNIQUE; TERTIARY CARE CENTER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY; ADENOCARCINOMA, FOLLICULAR; AGED; CARCINOMA; CARCINOMA, NEUROENDOCRINE; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; THYROID NEOPLASMS;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; BIOPSY, FINE-NEEDLE; CARCINOMA; CARCINOMA, NEUROENDOCRINE; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; OXYPHIL CELLS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROID NODULE;

EID: 84936930781     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2015.0049     Document Type: Article

References (31)

1. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR 2012 Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 367:705-715.
2. Walsh PS, Wilde JI, Tom EY, Reynolds JD, Chen DC, Chudova DI, Pagan M, Pankratz DG, Wong M, Veitch J, Friedman L, Monroe R, Steward DL, Lupo MA, Lanman RB, Kennedy GC 2012 Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules. J Clin Endocrinol Metab 97:E2297-2306.
3. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria and Explanatory Notes 2010 Springer, New York, N.Y.
4. Chudova D, Wilde JI, Wang ET, Wang H, Rabbee N, Egidio CM, Reynolds J, Tom E, Pagan M, Rigl CT, Friedman L, Wang CC, Lanman RB, Zeiger M, Kebebew E, Rosai J, Fellegara G, LiVolsi VA, Kennedy GC 2010 Molecular classification of thyroid nodules using highdimensionality genomic data. J Clin Endocrinol Metab 95:5296-5304.
5. Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW 2011 Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 96:E1719-1726.
6. Faquin WC 2013 Can a gene-expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma? Cancer Cytopathol 121: 116-119.
7. National Comprehensive Cancer Network, Inc. 2014 Clinical practice guidelines in oncology: Thyroid carcinoma, version 2.2014.Available at:www.nccn.org/professionals/physician- gls/pdf/thyroid.pdf (accessed November 20, 2014).
8. Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, Parker C, Steward DL, Mandel SJ, Haugen BR 2014 Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab 99:119-125.
9. Duick DS, Klopper JP, Diggans JC, Friedman L, Kennedy GC, Lanman RB, McIver B 2012 The impact of benign gene expression classifier test results on the endocrinologistpatient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid 22:996-1001.
10. Krane JF 2014 Lessons from early clinical experience with the Afirma gene expression classifier. Cancer Cytopathol 122:715-719.
11. Finley DJ, Zhu B, Fahey TJ 3rd 2004 Molecular analysis of Hurthle cell neoplasms by gene profiling. Surgery 136: 1160-1168.
12. Wada N, Duh QY, Miura D, Brunaud L, Wong MG, Clark OH 2002 Chromosomal aberrations by comparative genomic hybridization in Hurthle cell thyroid carcinomas are associated with tumor recurrence. J Clin Endocrinol Metab 87:4595-4601.
13. Erickson LA, Jalal SM, Goellner JR, Law ME, Harwood A, Jin L, Roche PC, Lloyd RV 2001 Analysis of Hurthle cell neoplasms of the thyroid by interphase fluorescence in situ hybridization. Am J Surg Pathol 25:911-917.
14. Mazzucchelli L, Burckhardt E, Hirsiger H, Kappeler A, Laissue JA 2000 Interphase cytogenetics in oncocytic adenomas and carcinomas of the thyroid gland. Hum Pathol 31:854-859.
15. Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, Ward DC 1999 Frequent chromosomal DNA unbalance in thyroid oncocytic (Hurthle cell) neoplasms detected by comparative genomic hybridization. Lab Invest 79:547-555.
16. McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, Kosok L, Reddi H 2014 An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 99:4069-4077.
17. Lastra RR, Pramick MR, Crammer CJ, LiVolsi VA, Baloch ZW 2014 Implications of a suspicious Afirma test result in thyroid fine-needle aspiration cytology: an institutional experience. Cancer Cytopathol 122:737-744.
18. Harrell RM, Bimston DN 2014 Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology. Endocr Pract 20:364-369.
19. Altman DG, Bland JM 1994 Diagnostic tests 2: Predictive values. BMJ 309:102.
20. Brito JP, Gionfriddo MR, Al Nofal A, Boehmer KR, Leppin AL, Reading C, Callstrom M, Elraiyah TA, Prokop LJ, Stan MN, Murad MH, Morris JC, Montori VM 2014 The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab 99:1253-1263.
21. Moon WJ, Jung SL, Lee JH, Na DG, Baek JH, Lee YH, KimJ, Kim HS, Byun JS, Lee DH, Thyroid Study Group, Korean Society of Neuro-and Head and Neck Radiology 2008 Benign and malignant thyroid nodules: US differentiation- multicenter retrospective study. Radiology 247:762-770.
22. Dettmer M, Vogetseder A, Durso MB, Moch H, Komminoth P, Perren A, Nikiforov YE, Nikiforova MN 2013 MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab 98:E1-7.
23. Musholt PB, Musholt TJ, Morgenstern SC, Worm K, Sheu SY, Schmid KW 2008 Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot. World J Surg 32:722-728.
24. Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, Socci N, Kannan K, Mo Q, Fagin JA, Chan TA 2013 Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab 98:E962-972.
25. de Vries MM, Celestino R, Castro P, Eloy C, Maximo V, van der Wal JE, Plukker JT, Links TP, Hofstra RM, Sobrinho-Simoes M, Soares P 2012 RET/PTC rearrangement is prevalent in follicular Hurthle cell carcinomas. Histopathology 61:833-843.
26. French CA, Alexander EK, Cibas ES, Nose V, Laguette J, Faquin W, Garber J, Moore F Jr, Fletcher JA, Larsen PR, Kroll TG 2003 Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 162: 1053-1060.
27. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE 2002 PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016-1023.
28. Cerutti JM, Oler G, Delcelo R, Gerardt R, Michaluart P Jr, de Souza SJ, Galante PA, Huang P, Riggins GJ 2011 PVALB, a new Hurthle adenoma diagnostic marker identified through gene expression. J Clin Endocrinol Metab 96:E151-160.
29. Kloos RT, Reynolds JD, Walsh PS, Wilde JI, Tom EY, Pagan M, Barbacioru C, Chudova DI, Wong M, Friedman L, LiVolsi VA, Rosai J, Lanman RB, Kennedy GC 2013 Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules? J Clin Endocrinol Metab 98:E761-768.
30. Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, Hodak SP, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN 2014 Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 120:3627-3634.
31. Aragon Han P, Olson MT, Fazeli R, Prescott JD, Pai SI, Schneider EB, Tufano RP, Zeiger MA 2014 The impact of molecular testing on the surgical management of patients with thyroid nodules. Ann Surg Oncol 21:1862-1869.